Loading...
News 2018-04-27T13:47:37+00:00

News

Number Title Author Date
Notice
2019.03.28. Alteogen wins patent on SC injection formulation for Herceptin biosimilar
alteogen | 2019.04.01 | Votes 0 | Views 8
alteogen 2019.04.01
26
Alteogen applies for P1 trial for Eylea biosimilar
alteogen | 2019.02.28 | Votes 0 | Views 60
alteogen 2019.02.28
25
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen | 2019.01.04 | Votes 0 | Views 150
alteogen 2019.01.04
24
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen | 2018.12.04 | Votes 0 | Views 113
alteogen 2018.12.04
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen | 2018.08.17 | Votes 0 | Views 133
alteogen 2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen | 2018.08.07 | Votes 0 | Views 116
alteogen 2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen | 2018.07.30 | Votes 0 | Views 124
alteogen 2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen | 2018.07.11 | Votes 0 | Views 104
alteogen 2018.07.11
19
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen | 2018.07.04 | Votes 0 | Views 107
alteogen 2018.07.04
18
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen | 2018.05.28 | Votes 0 | Views 137
alteogen 2018.05.28
17
23 Aug. 2017 Alteogen set to start phase I trial of ADC product in Korea
alteogen | 2018.05.28 | Votes 0 | Views 69
alteogen 2018.05.28